Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYOSEAL for incisional hernia prevention
NCT02584153Phase 1Withdrawn
- Sponsor
- Hobart Harris
- Start
- Jan 2019
- Primary completion
- Dec 2019
01
Overview
Phase 1, open-label, single-arm trial of MYOSEAL in incisional hernia, sponsored by Hobart Harris. Primary endpoints: Wound Occurrences at 6 months and Post-operative Complications at 6 months. Planned start Jan 2019; status: withdrawn.
02
Drugs
MYOSEAL
03
Conditions
incisional hernia
Beyond the preview
Go deeper on NCT02584153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584153.